CLINICAL TRIALS PROFILE FOR JANTOVEN
✉ Email this page to a colleague
All Clinical Trials for JANTOVEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02574754 ↗ | Assessment of 2012 Bioequivalence Standards for Warfarin | Completed | University of California, San Francisco | Phase 1 | 2016-05-01 | The purpose of this study is to assess the 2012 bioequivalence statistical criteria for warfarin, a narrow therapeutic index drug, set forth in the draft guidance issued by the Food and Drug Administration (FDA). |
| NCT02942407 ↗ | Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation | Completed | Bristol-Myers Squibb | Phase 4 | 2016-12-01 | This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) . |
| NCT02942407 ↗ | Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation | Completed | Christopher Granger | Phase 4 | 2016-12-01 | This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) . |
| NCT02942407 ↗ | Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation | Completed | Christopher Granger, MD | Phase 4 | 2016-12-01 | This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) . |
| NCT02943785 ↗ | Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) | Completed | Chiltern International Inc. | Phase 3 | 2017-03-21 | When the upper chambers of a person's heart receive irregular electrical signals it causes abnormal rhythm in the heart beat. This is called atrial fibrillation. Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients also get new heart valves using a catheter. Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is considered the standard care. This study will see how edoxaban compares to VKA in patients who got a new heart valve by using a catheter. The study will compare the two drugs for up to three years after heart valve replacement, looking at the drug's overall side effects (called adverse events) and major bleeding. |
| NCT02943785 ↗ | Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) | Completed | Daiichi Sankyo Inc. | Phase 3 | 2017-03-21 | When the upper chambers of a person's heart receive irregular electrical signals it causes abnormal rhythm in the heart beat. This is called atrial fibrillation. Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients also get new heart valves using a catheter. Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is considered the standard care. This study will see how edoxaban compares to VKA in patients who got a new heart valve by using a catheter. The study will compare the two drugs for up to three years after heart valve replacement, looking at the drug's overall side effects (called adverse events) and major bleeding. |
| NCT02943785 ↗ | Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) | Completed | Daiichi Sankyo, Inc. | Phase 3 | 2017-03-21 | When the upper chambers of a person's heart receive irregular electrical signals it causes abnormal rhythm in the heart beat. This is called atrial fibrillation. Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients also get new heart valves using a catheter. Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is considered the standard care. This study will see how edoxaban compares to VKA in patients who got a new heart valve by using a catheter. The study will compare the two drugs for up to three years after heart valve replacement, looking at the drug's overall side effects (called adverse events) and major bleeding. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for JANTOVEN
Condition Name
Clinical Trial Locations for JANTOVEN
Trials by Country
Clinical Trial Progress for JANTOVEN
Clinical Trial Phase
Clinical Trial Sponsors for JANTOVEN
Sponsor Name
